SUPN News Alert Supernus Pharmaceuticals Inc (SUPN) 8.52 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Supernus Pharmaceuticals Inc (SUPN) 8.52 $SUPN

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 31.32 (+0.26), CHTP: 6.52 (-0.03), SUPN: 8.52 (+0.15), ITCI: 17.99 (+0.16), LLY: 70.16 (+0.42), DRRX: 0.81 (-0.01)

Why Supernus Pharmaceuticals (SUPN) Might Be a Diamond in the Rough - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 7:54AM CST
Supernus Pharmaceuticals has been overlooked by investors but it has actually seen estimates rise over the past month.
SUPN: 8.52 (+0.15)

Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)

Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)

Supernus receives Paragraph IV ANDA filing for Trokendi XR from Par Pharmaceutical
M2 - Wed Dec 10, 6:32AM CST
Specialist pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Tuesday that it has received a Paragraph IV Notice Letter from Par Pharmaceutical for the filing of an Abbreviated New Drug Application for topiramate extended-release capsules.
SUPN: 8.52 (+0.15)

Supernus Announces Paragraph IV ANDA Filing for Oxtellar XR(R)
GlobeNewswire - Wed Dec 10, 6:30AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 9, 2014 the Company received a Paragraph IV Notice Letter from TWi Pharmaceuticals, Inc. ("TWi" advising Supernus of the filing by TWi of an Abbreviated New Drug Application seeking approval for oxcarbazepine extended-release tablets. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Oxtellar XR. The product is currently protected by four issued patents that expire no earlier than 2027.
SUPN: 8.52 (+0.15)

Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)
GlobeNewswire - Tue Dec 09, 8:12AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) today announced that on December 8, 2014 the Company received a Paragraph IV Notice Letter from Par Pharmaceutical, Inc. ("Par" advising Supernus of the filing by Par of an Abbreviated New Drug Application seeking approval for topiramate extended-release capsules. Supernus is currently reviewing the details of this Notice Letter and intends to vigorously enforce its intellectual property rights relating to Trokendi XR. The product is currently protected by five issued patents that expire no earlier than 2027.
SUPN: 8.52 (+0.15)

Why Supernus Pharmaceuticals (SUPN) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 7:30AM CST
Supernus Pharmaceuticals (SUPN) has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on SUPN’s earnings for the coming quarter and year.
SUPN: 8.52 (+0.15)

How Supernus Pharmaceuticals (SUPN) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 8:01AM CST
Supernus Pharmaceuticals is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 27
SUPN: 8.52 (+0.15)

Supernus receives fifth US patent for the antiepileptic drug Trokendi XR
M2 - Tue Nov 25, 8:15AM CST
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) revealed on Monday the receipt of the fifth patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release topiramate product, Trokendi XR.
SUPN: 8.52 (+0.15)

Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 5:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against Zydus accusing the latter of infringement of three patents covering Trokendi XR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)

Supernus Announces Issuance of Fifth U.S. Patent Protecting Trokendi XR(R)
GlobeNewswire - Mon Nov 24, 6:30AM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fifth patent (number 8,889,191) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.
SUPN: 8.52 (+0.15)

Supernus Sues Zydus for Infringement of Trokendi XR(R) Patents
GlobeNewswire - Fri Nov 21, 3:11PM CST
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) announced that it sued generic drug makers Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited (collectively "Zydus" for infringement of three patents covering its antiepileptic drug Trokendi XR(R). Supernus' United States Patents Nos. 8,298,576, 8,298,580, and 8,663,683 cover once-a-day topiramate formulations and methods of treating seizures using those formulations. Patent protection for Trokendi XR does not expire until 2029.
SUPN: 8.52 (+0.15)

Supernus Pharmaceuticals (SUPN) in Focus: Stock Up 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:32AM CST
Supernus Pharmaceuticals, Inc. (SUPN) was a big mover last session, as the company saw its shares nearly 10% on the day.
EVOK: 5.50 (-0.26), AKRX: 36.47 (+0.43), SUPN: 8.52 (+0.15)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 18, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 8.79 (+0.45), AFMD: 6.19 (+0.03), SUPN: 8.52 (+0.15), VYFC: 19.73 (-0.07), CVV: 14.81 (-0.09), MSBF: 10.15 (+0.05), MTEX: 28.96 (unch), JAXB: 12.26 (+0.96)

Supernus Pharmaceuticals (SUPN) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 12:01PM CST

SUPN: 8.52 (+0.15)

Supernus Pharma ups earnings 216% in Q3
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 11:59AM CST

SUPN: 8.52 (+0.15)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 8:18AM CST

ANV: 0.88 (+0.02), KEP: 19.78 (+0.05), RADA: 2.74 (+0.16), SEAS: 17.40 (-0.18), HPJ: 5.03 (+0.14), PLUG: 3.05 (-0.01), SUPN: 8.52 (+0.15), NBG: 1.95 (+0.06), GV: 2.25 (unch), OXGN: 1.59 (unch), NOAH: 20.44 (-1.00), FOSL: 109.78 (-0.20), AEO: 13.53 (+0.02), IBIO: 0.68 (-0.04), MTOR: 14.72 (+0.24), MLNX: 43.89 (+0.14), SUSQ: 13.43 (+0.01)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 4:38PM CST

HEAR: 2.98 (+0.01), FOSL: 109.78 (-0.20), SUPN: 8.52 (+0.15), ESSA: 11.69 (unch), YDLE: 12.65 (+0.20), LVS: 57.99 (-0.09), GOL: 5.16 (-0.04), OPWR: 14.88 (+0.12), KKD: 19.85 (-0.04), MATX: 34.61 (+0.11)

Supernus misses 3Q profit forecasts
Automated Insights - Tue Nov 11, 3:57PM CST
ROCKVILLE, Md. (AP) _ Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported third-quarter profit of $27.9 million.
SUPN: 8.52 (+0.15)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 109

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 109

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 97

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading

Top 5 Most Recently Viewed Articles

Arcline Investment Management Sells Resolution Medical to Resonetics

Updated Category News Views 213

Arcline Investment Management Sells Resolution Medical Arcline Investment Management, a dynamic private equity firm, has made a notable move in the medical technology landscape. The firm is set to sell its portfolio company, Resolution Medical, to Resonetics. This strategic decision highlights Arcline's ongoing commitment to advancing innovative solutions within the...

Continue Reading
Cheetah Mobile Surges with Impressive Q2 Financial Results

Updated Category News Views 223

Cheetah Mobile Reports Strong Growth in Q2 2025 Cheetah Mobile Inc. (NYSE: CMCM), a prominent IT company, has recently reported its financial results for the second quarter of 2025. The results indicate a remarkable increase in total revenue and profitability, showcasing the company’s ongoing strategic transformation. Management Insights on Performance Mr. Sheng Fu,...

Continue Reading
OwlTing Group Launches OwlPay Harbor for Enhanced Payment Solutions

Updated Category News Views 287

OwlTing Group Transforms Payments with AI-Powered OwlPay Harbor OwlTing Group, a pioneering blockchain fintech firm, has announced a significant evolution of its payment platform, OwlPay Harbor. This innovative service integrates artificial intelligence to enhance the experience for developers and users alike, making financial transactions faster and more secure than ever...

Continue Reading
Colt DCS Taps Nguyen for CEO Amid Growth Surge

Updated Category News Views 24

Nguyen Takes Helm at Colt DCS Well, here's a move that'll definitely shake the data center landscape a bit: Quy Nguyen's stepping up as the Chief Executive Officer at Colt Data Centre Services. From temporary to permanent, that decision speaks volumes about the trust in his leadership acumen during these transformative times. Colt's apparently betting the farm on Nguyen...

Continue Reading
NWR Storage Containers Expands with New Facility Opening

Updated Category News Views 143

NWR Storage Containers Expands with New Facility Opening NWR Storage Containers, a prominent provider of storage container rentals, is excited to announce its relocation to a larger facility. This event marks a significant step forward in their journey of growth and commitment to serving customers effectively. Relocation to a New Facility The newly established operations...

Continue Reading